Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Pfizer should partner with Sanofi
It's day three of the Pfizer-Sanofi merger watch. Sanofi-Aventis shares are up 5.5 percent on continued rumors of a Pfizer investment in its business. Now, experts are saying that a Sanofi acquisition wouldn't be prudent for Pfizer--but a partnership would.
If Pfizer just bought a stake in Sanofi, it could share in the French company's revenues. Sanofi would get access to Pfizer's U.S. sales force. And the companies wouldn't have to get the French government's blessing on this sort of deal--a blessing that might be hard to come by.
- read the report from Fortune
Related Articles:
Pfizer-Sanofi match not made in heaven? Report
Sanofi stock up on Pfizer buyout talk. Report
Pfizer, Wyeth merger bad idea? Report
Read more on: Pfizer | Sanofi-Aventis
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
